301232-43-9

Basic information

• Product Name: 1-Boc-4-(3-oxo-3-phenylpropyl)piperidine
• Synonyms: 1-Boc-4-(3-oxo-3-phenylpropyl)piperidine;tert-butyl 4-(3-oxo-3-phenylpropyl)piperidine-1-carboxylate
• CAS NO: 301232-43-9
• Molecular Formula: C₁₉H₂₇NO₃
• Molecular Weight: 317.42258
• Mol File: 301232-43-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 428.5°C at 760 mmHg
• Flash Point: 212.9°C
• Appearance: /
• Density: 1.064g/cm³
• Vapor Pressure: 1.51E-07mmHg at 25°C
• Refractive Index: 1.518
• CAS DataBase Reference: 1-Boc-4-(3-oxo-3-phenylpropyl)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-(3-oxo-3-phenylpropyl)piperidine(301232-43-9)
• EPA Substance Registry System: 1-Boc-4-(3-oxo-3-phenylpropyl)piperidine(301232-43-9)

Safety Data

• Hazardous Substances Data: 301232-43-9(Hazardous Substances Data)

Usage

Chemical structure

Piperidine derivative with a tert-butoxycarbonyl (Boc) protecting group at the N-1 position and a 3-oxo-3-phenylpropyl substituent at the 4-position.

Functional groups

a. Boc protecting group
b. Piperidine ring
c. 3-oxo-3-phenylpropyl substituent

Applications

a. Building block in organic synthesis
b. Preparation of pharmaceuticals and biologically active compounds

Pharmacological properties

a. Potential analgesic effects
b. Potential anesthetic effects

Research areas

a. Ligand in the synthesis of metal complexes for catalysis
b. Other applications in medicinal chemistry and related fields

InChI:InChI=1/C19H27NO3/c1-19(2,3)23-18(22)20-13-11-15(12-14-20)9-10-17(21)16-7-5-4-6-8-16/h4-8,15H,9-14H2,1-3H3

Upstream product

• 291289-27-5 4-(3-oxo-3-phenyl-propenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 6457-49-4 4-piperidinemethanol 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 29526-96-3 1-phenylcyclopropan-1-ol 
• 1872262-73-1 1-(tert-butyl) 4-(1,3-dioxoisoindolin-2-yl) piperidine-1,4-dicarboxylate 
• 498-94-2 isonipecotic acid 
• 858644-32-3 1,1-dimethylethyl 4-[(1E)-3-oxo-3-phenyl-1-propenyl]-1-Piperidinecarboxylate 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 100-58-3 phenylmagnesium bromide 
• 301186-40-3 N-methoxy-N-methyl-3-(1-(tert-butoxycarbonyl)piperidin-4-yl)propionamide 

Downstream Products

• 914654-70-9 methyl 2-({3-[(piperidin-4-yl)methyl]-2-phenylquinolin-4-yl}carbonyl)-1-phenylhydrazinecarboxylate 
• 914654-66-3 3-({1-[(1,1-dimethylethoxy)carbonyl]piperidin-4-yl}methyl)-N',2-diphenylquinoline-4-carbohydrazide 
• 914654-67-4 Methyl 2-{[3-({1-[(1,1-Dimethylethoxy)carbonyl]piperidin-4-yl}methyl)-2-phenylquinolin-4-yl]carbonyl}-1-phenylhydrazinecarboxylate 
• 923024-07-1 3-{[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}-8-fluoro-2-phenylquinoline-4-carboxylic acid 
• 301232-56-4 4-(3-oxo-3-phenylpropyl)piperidine trifluoroacetate 
• 914654-64-1 3-{1-[(1,1-dimethylethoxy)carbonyl]piperidin-4-yl}methyl-2-phenylquinoline-4-carboxylic acid 

Relevant articles and documents

Ni-Catalyzed β-Alkylation of Cyclopropanol-Derived Homoenolates

Metal homoenolates are valuable synthetic intermediates which provide access to β-functionalized ketones. In this report, we disclose a Ni-catalyzed β-alkylation reaction of cyclopropanol-derived homoenolates using redox-active N-hydroxyphthalimide (NHPI) esters as the alkylating reagents. The reaction is compatible with 1°, 2°, and 3° NHPI esters. Mechanistic studies imply radical activation of the NHPI ester and 2e β-carbon elimination occurring on the cyclopropanol.

Quinoline derivatives as neurokinin receptor antagonists

The present invention relates to substituted quinoline hydrazides of Formula (I): wherein R1, R2, R3, R4, R5, X, Y and Z are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.

N′,2-Diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II

Introduction of selected amine containing side chains into the 3-position of N′,2-diphenylquinoline-4-carbohydrazide based NK3 antagonists abolishes unwanted hPXR activation. Introduction of a fluorine at the 8-position is necessary to minimize unwanted hIKr affinity and a piperazine N-tert-butyl group is necessary for metabolic stability. The lead compound (8m) occupies receptors within the CNS following oral dosing (Occ90 7 mg/kg po; plasma Occ90 0.4 μM) and has good selectivity and excellent PK properties.